Virus Research Publications citing the use of ProImmune Pentamers

Have you published a paper citing the use of ProImmune’s products or services? If so, please send us a reprint as a PDF by e-mail to enquiries@www.proimmune.com. We will send you a bottle of Champagne to celebrate with! (Limited to 1 bottle per publication).

Adenovirus Human Immunodeficiency Virus (HIV)
Cytomegaolvirus (CMV) Human T-lymphotropic Virus (HTLV)
Epstein-Barr Virus (EBV) Human Papillomavirus (HPV)
Hepatitis B (HBV) Lymphocytic Choriomeningitis Virus (LCMV)
Hepatitis C (HCV) Respiratory Syncytial Virus (RSV)
Human Herpes Virus (HHV/HSV) Vaccinia Virus

Adenovirus

Finn, JD. et al. (2010). Proteasome inhibitors decrease AAV2 capsid-derived peptide epitope presentation on MHC class I following transduction. Molecular Therapy. 18: 135-142[PubMedID:19904235]

B*07:02/VPQYGYLTL (AAV-2)

Fujita, Y. et al. (2008) Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 31: 665-674. [PubMedID: 18600178]

B*35:01/MPNRPNYIAF (Adenovirus 5 Hexon)
A*02:01/NLVPMVATV (CMV pp65)
A*02:01/FLYALALL (EBV LMP-2)
A*02:01/CLGGLLTMV (EBV LMP-2)

Geyeregger, R. et al. (2013) Short-term in-vitro expansion improves monitoring and allows affordable generation of virus-specific T-cells against several viruses for a broad clinical application. PLoS One. 8(4):e59592. [PubMedID: TBC]

A*01:01/TDLGQNLLY (Adenovirus 5 Hexon 886-894)
A*24:02/TYFSLNNKF (Adenovirus 5 Hexon 37-45)
B*07:02/KPYSGTAYNAL (Adenovirus Hexon 114-124)
B*35:01/MPNRPNYIGF

Joshi et al. (2011).Comparison of Human Memory CD8 T Cell Responses to Adenoviral Early and Late Proteins in Peripheral Blood and Lymphoid Tissue PLoS One. 6:e20068. [PubMedID:21637763]

Kaka, AS. et al. (2008). Using dendritic cell maturation and IL-12 producing capacity as markers of function: A cautionary tale. J Immunother. 31: 359-369. [PubMedID: 18391760]

A*01:01/TLDGQNLLY (Adenovirus 5 Hexon)
A*24:02/TYFSLNNKF (Adenovirus 5 Hexon)

Karlsson, H. et al. (2007) Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus and Epstein-Barr virus. J. Immunother. 30: 544-556. [PubMedID: 17589295]

A*24:02/TYFSLNNKF (Adenovirus 5 Hexon)
A*01:01/TLDGQNLLY (Adenovirus 5 Hexon)
B*07:02/KPYSGTAYNAL (Adenovirus Hexon)

Leen, AM. et al. (2008). Identification of Hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 82: 546-554. [PubMedID: 17942545]

A*24:02/TYFSLNNKF (Adenovirus 5 Hexon)
A*01:01/TLDGQNLLY (Adenovirus 5 Hexon)
B*07:02/KPYSGTAYNAL (Adenovirus Hexon)
B*35:01/MPNRPNYIAF (Adenovirus 5 Hexon)

Micklethwaite, KP. et al. (2008). Prophylactic infusion of cytomegalovirus-specific cytotoxic T lymphocytes stimulated with Ad5f35pp65 gene modified dendritic cells after allogeneic hemopoietic stem cell transplantation. Blood. 112: 3974-3981 [PubMedID: 18768783]

A*01:01/TDLGQNLLY (Adenovirus 5 Hexon)

Mingozzi, F. et al. (2007). CD8+ T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13: 419-422. [PubMedID:17369837]

B*07:02/VQPYGYLTL (AAV-2)

Pazos et al (2012) Estrogen Mediates Innate and Adaptive Immune Alterations to Influenza Infection in Pregnant Mice PLoS One 7:e40502 [PubMedID:22792357]

Pien, GC. et al. (2009). Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. Journal Clin. Invest. 119:1688. [PubMedID: 19436115]

B*07:02/VQPYGYLTL (AAV-2)
B*07:02/IPQYGYLTL (AAV-8)
B*07:02/IPRRIRQGL (HIV-1 env)
B*07:02/RPPIFIRRL (EBV EBNA-3A)

Schotsaert et al (2012) Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunology [PubMedID:22806098]

Vasconcelos et al (2012) Pathogen-Induced Proapoptotic Phenotype and High CD95 (Fas) Expression Accompany a Suboptimal CD8+ T-Cell Response: Reversal by Adenoviral Vaccine PLoS Pathogens 8:e1002699 [PubMedID:22615561]

Vasconcelos et al (2014) Adenovirus Vector-Induced CD8+ T Effector Memory Cell Differentiation and Recirculation, But Not Proliferation, Are Important for Protective Immunity Against Experimental Trypanosoma cruzi Infection. Human Gene Therapy. 25:4, pp. 350-63. [PubMedID:24568548]

H-2Kb/VNHRFTLV (ASP-2)

(back to top)

 

Cytomegalovirus (CMV)

Albon et al. (2013). Optimization of methodology for production of CD25/CD71 allodepleted donor T cells for clinical use. Cytotherapy. 15: 109-121. [PubMedID: 23260091]

A*02:01/NLVPMVATV (HCMV pp65 495-504)

Ameres, S. et al (2013). Presentation of an Immunodominant Immediate-Early CD8+ T Cell Epitope Resists Human Cytomegalovirus Immunoevasion. 9(5) [PubMedID: 23717207]

Böhm, V. et al. (2008). Epitope-specific in vivo protection against cytomegalovirus disease by CD8 T cells in the murine model of preemptive immunotherapy. Med. Microbiol. Immunol. 197:135-144.[PubMedID:18340461]

H-2Ld/YPHFMPTNL (MCMV)

Bollard, C.M. et al. (2007).Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 110: 2838-45. [PubMedID:17609424]

A*02:01/CLGGLLTMV (EBV LMP-2)
A*02:01/NLVPMVATV (HCMV pp65)

Bererhi et al (2012) Clinical and immunological features of very long-term survivors with a single renal transplant Transplant International epub [PubMedID:22353435]

Brennan et al (2012) The Impact of a Large and Frequent Deletion in the Human TCR β Locus on Antiviral Immunity Journal of Immunology epub [PubMedID:22323539]

Brennan, R.M. et al. (2007).Predictable ab T cell receptor selection towards an HLA-B*35:01-restricted human cytomegalovirus epitope. J. Virol. 81: 7269-7273. [PubMedID:17459926]

B*35:01/IPSINVHHY(HCMV pp65)

Brestrich et al (2009) Adoptive T-Cell Therapy of a Lung Transplanted Patient with Severe CMV Disease and Resistance to Antiviral Therapy. American J. Transplant. 9:1679 [PubMedID:19459791]

Cantisan, S. et al. (2012) Role of Defective Thymic Function in Onset of Ganciclovir-Resistant Cytomegalovirus after Cord Blood Transplantation. Clin. Vaccine Immunol. 19: 1994-1998 [PubMedID:23054743]

A*02:01/NLVPMVATV (CMV pp65)

Cantisan, S. et al. (2009) Age-dependent association between low frequency of CD27/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation. Clin. Vaccine Immunol. 16: 1429-1438 [PubMedID:19656991]

A*02:01/NLVPMVATV (CMV pp65)

Cieri et al. (2012). IL-7 and IL-15 instruct the generation of human memory stem T cells from naïve precursors. Blood, epub ahead of print. [PubMedID:23160470]

A*02:01/NLVPMVATV (CMV pp65)

Christmas, SE. et al. (2009). Cytomegalovirus-specific CD8+ T ells do not develop in all renal transplant patients at risk of virus infection. Transpl. Immunol. 22: 99-104 [PubMedID:19635559]

A*02:01/NLVPMVATV (CMV pp65)

Crough, T. et al. (2012). Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme. Immunology and Cell Biology. [PubMedID:22508289]

Crough, T. et al. (2007). Symptomatic and asymptomatic viral recrudescence in solid organ transplant recipients and its relationship with antigen-specific CD8+ T-cell response. J. Virol. 81: 11538-42. [PubMedID: 17686874]

A*02:01/NLVPMVATV (CMV pp65)
A*01:01/VTEMDTLLY (CMV pp50)
B*07:02/TPRVTGGGAM (CMV pp65)

Czesnikiewicz-Guzik, M. et al. (2008) T cell subset-specific susceptibility to aging.Clin Immunol. 127: 107-118 [PubMedID: 18222733]

A*02:01/NLVPMVATV (CMV pp65)

Dander, E. et al. (2008). Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library. Exp. Hematol. 36: 473-485. [PubMedID: 18261836]

A*02:01/NLVPMVATV (CMV pp65)
B*07:02/TPRVTGGGAM (CMV pp65)
B*07:02/RPHERNGFTVL (CMV pp65)
A*01:01/YSEHPTFTSQY (CMV pp65)
B*35:01/IPSINVHHY (CMV pp65)

Davies, JK. et al. (2008). Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of two phase I studies. Blood. 112: 2232-2241 [PubMedID: 18617635]

A*02:01/NLVPMVATV (CMV pp65)

Davies, JK et al (2008). Induction of alloanergy in human donor T cells without loss of pathogen or tumour immunity. Transplantation. 86: 854-864 [PubMedID: 18813111]

A*02:01/GLCTLVAML (EBV BMLF-1)
A*02:01/NLVPMVATV (CMV pp65)

Flinsenberg T.W.H. et al (2014) Cognate CD4 T-cell licensing of dendritic cells heralds anti-CMV CD8 T-cell immunity after human allogeneic umbilical cord blood transplantation. Journal of Virology. [Published ahead of print 5 November 2014][PubMedID: 25378489]

Fujita, Y. et al. (2008) Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 31: 665-674. [PubMedID: 18600178]

B*35:01/MPNRPNYIAF (Adenovirus 5 Hexon)
A*02:01/NLVPMVATV (CMV pp65)
A*02:01/FLYALALL (EBV LMP-2)
A*02:01/CLGGLLTMV (EBV LMP-2)

Ge et al (2008) CD134-Allodepletion Allows Selective Elimination of Alloreactive Human T Cells without Loss of Virus-Specific and Leukemia-Specific Effectors. Biology of Blood and Marrow Transplantation 14:518 [PubMedID:18410894]

Gerdemann, U. et al. (2009). Nucleofection of DCs to generate multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised host. Molecular Therapy. 17: 1616-1625. [PubMedID: 19584818]

A*02:01/NLVPMVATV (CMV pp65)
B*07:02/TPRVTGGGAM (CMV pp65)

Ghazi et al (2012) Generation of Polyclonal CMV-specific T Cells for the Adoptive Immunotherapy of Glioblastoma Journal of Immunotherapy 35:159  [PubMedID:22306904]

Griffiths, S. J. et al (2013) Age-associated increase of low-avidity cytomegalovirus-specific CD8+ T cells that re-express CD45RA. J. Immunol. Epub ahead of print. [PubMedID:23636061]

A*02:01/NLVPMVATV (HCMV pp65 495-504)

Griffioen, M. et al (2008). Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica. 93: 1535-1543 [PubMedID: 18768532]

Hayashi, D. et al. (2008). Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-1-associated myelopathy. J Neuroimmunol. 200: 115-124 [PubMedID: 18639344]

A*02:01/LLFGYPVYV (HTLV Tax)
A*02:01/CLGGLLTMV (CMV LMP2)
A*02:01/NLVPMVATV (CMV pp65)
A*02:01/SLYNTVATL (HIV gag17)

Hervas-Stubbs, S. et al. (2010). Effects of IFN-a as a signal-3 cytokine on human naive and antigen-experienced CD8+ T cells. European Journal of Immunology 40: 3389-3402. [PubMedID: 21108462]

Hill et al (2010) Successful Immunotherapy of HCMV Disease Using Virus-Specific T Cells Expanded from an Allogeneic Stem Cell Transplant Recipient. American Journal of Transplantation 10:173 [PubMedID:19919660]

Holubova et al (2012) Delivery of large heterologous polypeptides across the cytoplasmic membrane of antigen presenting cells by Bordetella RTX ‘hemolysin’ moiety lacking the adenylyl cyclase domain.  Infection and Immunity epub [PubMedID:22215742]

Horlock, C. et al. (2009). ELISPOT and functional T cell analyses using HLA mono-specific target cells. J Immunol. Methods 350: 150-160. [PubMedID: 19729014]

Jelinek et al (2011) In vitro activation of CMV-specific human CD8+ T cells by adenylate cyclase toxoids delivering pp65 epitopes. Bone Marrow Transplantation 47:243  [PubMedID:21441962]

Karlsson, H. et al. (2007) Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus and Epstein-Barr virus. J. Immunother. 30: 544-556. [PubMedID: 17589295]

A*02:01/NLVPMVATV (HCMV pp65)
B*07:02/RPHERNGFTVL (HCMV pp65)
B*07:02/TPRVTGGGAM (HCMV pp65)
A*02:01/CLGGLLTMV (EBV LMP-2)
A*02:01/GLCTLVAML (EBV BMLF-1)
B*07:02/RPPIFIRRL (EBV EBNA-3A)
B*08:01/RAKFKQLL (EBV BZLF-1)
A*24:02/TYFSLNNKF (Adenovirus 5 Hexon)
A*01:01/TLDGQNLLY (Adnovirus 5 Hexon)
B*07:02/KPYSGTAYNAL (Adenovirus Hexon)

Karlsson, H. et al. (2008). Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T cell responses. Blood 112: 532-541 [PubMedID: 18445691]

A*02:01/NLVPMVATV (HCMV pp65)
B*07:02/RPHERNGFTVL (HCMV pp65)
B*07:02/TPRVTGGGAM (HCMV pp65)
A*02:01/GLCTLVAML (EBV BMLF-1)
B*07:02/RPPIFIRRL (EBV EBNA-3A)
B*08:01/RAKFKQLL (EBV BZLF-1)

Kuntz et al (2011) Analysis of bulk and virus-specific CD8+ T cells reveals advanced differentiation of CD8+ T cells in patients with common variable immunodeficiency. Clinical Immunology 141:177 [PubMedID: 21873117]

Leen et al (2011) Monitoring of Cytomegalovirus-Specific CD8+ T-Cell Response With Major Histocompatibility Complex Pentamers in Kidney Transplant Recipients. Transplantation Proceedings 43: 2636 [PubMedID: 21911137]

Leen, A.M. et al. (2006). Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat. Med. 12: 1160-1166. [PubMedID: 16998485]

A*02:01/NLVPMVATV (HCMV pp65)
A*24:01/VYALPLKML (HCMV pp65)
A*24:01/QYDPVAALF (HCMV pp65)
B*07:02/RPHERNGFTVL (HCMV pp65)
B*07:02/TPRVTGGGAM (HCMV pp65)

Li Pira et al (2007) Helper function of cytolytic lymphocytes: Switching roles in the immune response. European Journal of Immunology 37:66 [PubMedID:17171758]

Li Pira, G. et al. (2008) Positive selection and expansion of cytomegalovirus-specific CD4 and CD8 T cells in sealed systems. Potential applications for adoptive cellular immunoreconstitution. J Immunother. 31: 762-770. [PubMedID: 18779743]

A*02:01/NLVPMVATV (HCMV pp65)

Li Pira, G. et al. (2008). Evaluation of antigen specific T-cell responses with a miniaturized and automated method. Clin. Vaccine Immunol. 15: 1811-1818 [PubMedID: 18945878]

A*02:01/NLVPMVATV (CMV pp65)

Li Pira, G. et al. (2006). A sealed and unbreached system for purification, stimulation, and expansion of cytomegalovirus-specific human CD4 and CD8 T lymphocytes. Transfusion 46: 2053-62. [PubMedID: 17176316]

A*02:01/NLVPMVATV (CMV pp65)
A*02:01/SLYNTVATL (HIV gag p17)

Liu et al (2014) Preliminary exploration of HLA-A*1101-restricted human cytomegalovirus glycoprotein B-specific CD8+ T cells in allogeneic stem-cell transplant recipients. Virus Research. 188(08) pp. 38-44. [PubMedID:24704672]

Luo et al (2012) Immune reconstitution to cytomegalovirus following partially matched-related donor transplantation: impact of in vivo T-cell depletion and granulocyte colony-stimulating factor-primed peripheral blood/bone marrow mixed grafts Transplant Infectious Disease epub[PubMedID:22372613]

Luo et al (2010) Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16:994[PubMedID:20167279]

Marashi et al (2011) Inflammation in common variable immunodeficiency is associated with a distinct CD8+ response to cytomegalovirus. Journal of Allergy and Clinical Immunology 127:1385 [PubMedID:21536322]

Marashi et al (2012) Influence of cytomegalovirus infection on immune cell phenotypes in patients with common variable immunodeficiency. Journal of Allergy and Clinical Immunology 129:1349[PubMedID:22444511]

Martin-Donnaire, T. et al. (2009). Immune reconstitution after cord blood transplants supported by coinfusion of mobilized hematopoietic stem cells from a third party donor. Bone Marrow Transplantation. 44: 213-225 [PubMedID: 19252533]

A*02:01/NLVPMVATV (CMV pp65)
A*01:01/YSEHPTFTSQY (CMV pp65)
A*24:02/QYDPVAALF (CMV pp65)
A*24:02/VYALPLKML (CMV pp65)
B*35:01/IPSINVHHY (CMV pp65)

Miconnet et al. (2011) Large TCR Diversity of Virus-Specific CD8 T Cells Provides the Mechanistic Basis for Massive TCR Renewal after Antigen Exposure. Journal of Immunology 186:7039 [PubMedID: 21555537]

Mustjoki, S. et al. (2009) Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 23: 1398-1405 [PubMedID: 19295545]

Paine, A. et al. (2007). Expansion of human cytomegalovirus-specific T lymphocytes from unfractionated peripheral blood mononuclear cells with artificial antigen-presenting cells. Transfusion 47: 2143-52. ]PubMedID: 17958544]

A*02:01/NLVPMVATV (CMV pp65)
A*02:01/VLHDDLLEA (HA-1) – Negative control

Peggs et al (2009) Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation. Clinical Infectious Diseases 49:1851 [PubMedID:19911966]

Peggs, K. et al. (2010). Directly Selected Cytomegalovirus-Reactive Donor T Cells Confer Rapid and Safe Systemic Reconstitution of Virus-Specific Immunity Following Stem Cell Transplantation. Clinical Infectious Diseases. 52:49-57. [PubMedID: 21148519]

A*02:01/NLVPMVATV (CMV pp65)
B*07:02/RPHERNGTVL (CMV pp65)

Perseghin, P. et al. (2008). Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation device. Transfusion. 48: 1644-1649. [PubMedID: 18513258]

A*02:01/NLVPMVATV (CMV pp65)

Pita-Lopez, ML. et al. (2009). Effect of ageing on CMV-specific CD8 T cells from CMV seropositive healthy donors. Immunity & Ageing. 6: 11 [PubMedID:19715573]

A*02:01/NLVPMVATV (CMV pp65)

Provenzano et al (2009) A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a wide range of HLA specificities. J Cell Mol Med. 13:2131 [PubMedID:19604317]

Reker Hadrup, S. et al. (2006). Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J. Immunol. 176: 2645-2653.[PubMedID: 16456027]

A*02:01/NLVPMVATV (HCMV pp65)
A*02:01/GLCTLVAML (EBV BMLF-1)
A*02:01/ILKEPVHGV (HIV-1 pol)

Rosenthal, R. et al. (2009). Differential responsiveness to IL-2, IL-7 and Il-15 common receptor gchain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients. J Immunother. 32: 252-261. [PubMedID: 19242375]

A*02:01/NLVPMVATV (CMV pp65)
A*02:01/GLCTLVAML (EBV BMLF-1)
A*02:01/ELAGIGILTV (MelanA/MART-1)
A*02:01/SLSAYIIRV (Vaccinia Virus H3L)
A*02:01/KVDDTFYYV (Vaccinia Virus C7L)

Schub, A et al. (2009). CMV-specific TCR transgenic T cells for immunotherapy. J Immunol: 183: 6819-6830 [PubMedID: 19864595]

A*01:01/YSEHPTFTSQY (CMV pp65)
A*02:01/NLVPMVATV (CMV pp65)
B*35:01/IPSINVHHY (CMV pp65)

Schultz-Thater, E. et al. (2008). Whole blood assessment of antigen specific cellular immune response by real time quantitative PCR: a versatile monitoring and discovery tool. Journal of Translational Medicine. 6: 58 [PubMedID: 18925935]

A*02:01/NLVPMVATV (CMV pp65)
A*02:01/GLCTLVAML (EBV BMLF1)
A*02:01/CLGGLLTMV (EBV LMP2)
A*02:01/GILGFVFTL (Influenza MP)

Schwanninger, A. et al. (2008). Age-related appearance of a CMV-specific high-avidity CD8+ T cells clonotype which does not occur in young adults. Immunity & Ageing. 5:14 [PubMedID: 19014475]

A*02:01/NLVPMVATV (CMV pp65)

Seiler et al (2007) Dendritic Cell Function After Gene Transfer with Adenovirus-calcium Phosphate Co-precipitates.  Molecular Therapy 15:386 [PubMedID:17235318]

Sester, U. et al. (2008). PD-1 expression and IL-2 loss of cytomegalovirus-specific T cells correlates with viremia and reversible functional anergy. Am J Transplant. 8: 1486-1497 [PubMedID: 18510628]

A*01:01/YSEHPTFTSQY (CMV pp65)

Siegel et al (2012) Factors That Determine the Antiviral Efficacy of HCV-Specific CD8+ T Cells Ex Vivo. Gastroenterology. epub [PubMedID:23142136]

A*02:01/NLVPMVATV(HCMV pp65 495-504)
A*02:01/GLCTLVAML (EBV BMLF-1 259-267)

Stuehler et al (2009) Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. Blood 114:2829[PubMedID:19657113]

Suneetha, PV. et al. (2009). Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. J Immunol. Methods 342: 33-48. [PubMedID: 19135447]

A*02:01/GILGFVFTL (Influenza MP)
A*02:01/NLVPMVATV (CMV pp65)
A*02:01/GLCTLVAML (EBV BMLF-1)
A*02:01/CINGVCWTV (HCV NS3)

Tanaka, K. et al. (2007). Role of the indigenous microbiota in maintaining the virus-specific CD8 memory T cells in the lung of mice infected with murine cytomegalovirus. J. Immunol. 178: 5209-5216. [PubMedID: 17404304]

H-2Ld/YPHFMPTNL (MCMV)

Tey, S-K. et al. (2010). CD8+ T-cell recognition of human cytomegalovirus latency-associated determinant pUL138. J. General Virology 91: 2040-2048. [PubMedID:20375220]

B*35:01/IPSINVHHY(CMV pp65)
A*01:01/VTEHDTLLY(CMV pp50)

Tey, S-K. et al. (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol. Blood Marrow Transplant. 13: 913-24. [PubMedID: 17640595]

B*08:01/RAKFKQLL (EBV BZLF-1)
A*02:01/NLVPMVATV (CMV pp65)

Tischer, S. et al (2011) Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies. Journal of Translational Medicine 9:175 [PubMed ID: 21992180]

Tischer et al (2012) Establishment of the reversible peptide-major histocompatibility complex (pMHC) class I Histamer technology: tool for visualization and selection of functionally active antigen-specific CD8+ T lymphocytes. International Immunology [PubMedID:22740564]

Vera et al (2011) Accelerated production of antigen-specific T-cells for pre-clinical and clinical applications using Gas-permeable Rapid Expansion cultureware (G-Rex). Journal of Immunotherapy 33:305  [PubMedID: 20445351]

Wallace, D. et al. (2011). Human cytomegalovirus-specific CD8+ T-cell expansions contain long-lived cells that retain functional capacity in both young and elderly subjects. Immunology. 132: 27. [PubMedID:20738423]

Waller, E. et al. (2007). Differential co-stimulation through CD137 (4-1BB) restores proliferation of human virus-specific “effector memory” (CD28-CD45RA hi) CD8+ T cells. Blood. 110: 4360-6. [PubMedID:17878400]

A*02:01/NLVPMVATV (CMV pp65)
B*07:02/TPRVTGGGAM (CMV pp65)

Weinberger, B et al. (2009). CD28CD8+ T cells do not contain unique clonotypes and are therefore dispensable. Immunol Lett. 127: 37-32 [PubMedID:19715728]

A*02:01/NLVPMVATV (CMV pp65)

Widmann, T. et al. (2008) Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation. PLoS ONE. 3: e3634 [PubMedID:18982061]

A*01:01/YSEHPTFTSQY (CMV pp65)
A*02:01/NLVPMVATV (CMV pp65)
A*02:01/VLEETSVML (CMV 1E1)
B*07:02/TPRVTGGGAM (CMV pp65)
B*07:02/RPHERNGTVL (CMV pp65)

Wilson, J. et al. (2009). Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease. J. Exp. Med. 206: 387-398 [PubMedID:19171763]

A*02:01/NLVPMVATV (CMV pp65)

Wynn, KK. et al. (2008). Impact of lonal competition for peptide-MHC complexes on CD8+ T cell repertoire selection in a persistent viral infection. Blood. 111: 4283-4292. [PubMedID:18270323]

B*35:08/CPSQEPMSIYVY (CMV pp65)
B*35:08/FPTKDVAL (CMV pp65)

Yang, R. et al. (2008) Human Cytomegalovirus specific CD8+ T lymphocytes display interferon-gsecretion impairment in kidney transplant recipients with pp65 antigenemia. Transplantation Proc. 40: 3500-3504 [PubMedID:19100424]

A*02:01/NLVPMVATV (CMV pp65)

Yao, J. et al. (2008). Multimer staining of cytomegalovirus phosphoprotein 65-specific T cells for diagnosis and therapeutic purposes: a comparative study. Clin Infect Dis. 46:e96-105. [PubMedID:18419478]

A*02:01/NLVPMVATV (HCMV pp65)
B*07:02/TPRVTGGGAM (CMV pp65)

Zhang, J-Y. et al. (2008) Cutting Edge: Programmed Death-1 up-regulation is involved in the attrition of cytomegalovirus-specific CD8+ T cells in acute self-limiting hepatitis B virus infection. J. Immunol. 181: 3741-3744 [PubMedID:18768824]

A*02:01/NLVPMVATV (CMV pp65)

Zhang, X. et al. (2006). Human bone marrow: A reservoir for ‘enhanced effector memory’ CD8+ T cells with potent recall function. J. Immunol. 177: 6730-6737. [PubMedID: 17082586]

A*02:01/NLVPMVATV (CMV pp65)

Zhong, J. et al. (2008). Induction of pluripotent protective immunity following immunisation with a chimeric vaccine against human cytomegalovirus. PLoS one. 3:e3256 [PubMedID:18806877]

A*02:01/NLVPMVATV (CMV pp65)
A*01:01/VTEHDTLLY (CMV pp50)

Wang, X. et al. (2007). Induction of potent CD8+ T cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type I gp120. J. Virol. 81: 10009-16. [PubMedID:17609261]

A*02:01/NLVPMVATV (CMV pp65)
B*07:02/TPRVTGGGAM (CMV pp65)

Wussow et al. (2013). A Vaccine Based on the Rhesus Cytomegalovirus UL128 Complex Induces Broadly Neutralizing Antibodies in Rhesus Macaques. J. Virol. 87: 1322-1332. [PubMedID:23152525]

(back to top)

 

Epstein-Barr Virus (EBV)

Albon et al. (2013). Optimization of methodology for production of CD25/CD71 allodepleted donor T cells for clinical use. Cytotherapy. 15: 109-121. [PubMedID: 23260091]

A*02:01 GLCTLVAML (EBV BMLF-1 259-267)
A*02:01 CLGGLLTMV (EBV LMP-2 426-434)
B*07:02 RPPIFIRRL (EBV EBNA-3A 247-255)
B*08:01 RAKFKQLL (EBV BZLF-1 190-197)

Angelini, D.F. et al. (2013). Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathogens. 9(4): e1003220. [PubMedID:23592979]

A*02:01/GLCTLVAML (EBV BMLF-1 259-267)
B*08:01/RAKFKQLL (EBV BZLF-1 190-197)
A*02:01/CLGGLLTMV (EBV LMP-2 426-434)
B*08:01/FLRGRAYGL (EBV EBNA-3A)
A*02:01/NLVPMVATV (HCMV pp65 495-504)

Archbold, J.K. et al. (2006). Alloreactivity between disparate cognate and allogeneic pMHC-I complexes is resultant of highly focused, peptide-dependent structural mimicry. J.Biol. Chem. 281: 34324-34332. [PubMedID: 16963442]

B*08:01/FLRGRAYGL (EBV EBNA-3A)

Bell, MJ. et al. (2008) Widespread sequence variation in Epstein-Barr virus nuclear antigen 1 influences the antiviral T cell response. J. Infect. Dis. 197: 1594-1597 [PubMedID: 18419576]

B*08:01/YNLRRGIAL (EBV EBNA1)
B*08:01/YNLRRGTAL (EBV EBNA1)

Bell, MJ. et al. (2009) An HLA-A2-restricted T cell epitope mapped to the BNLF2a immune evasion protein of EBV that inhibits TAP. J Virol.83: 2783-2788 [PubMedID: 19129449]

A*02:01/VLFGLLCLL (EBV BNLF2a)

Bollard, C.M. et al. (2007). Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood. 110: 2838-45. [PubMedID: 17609424]

A*02:01/CLGGLLTMV (EBV LMP-2)
A*02:01/NLVPMVATV (HCMV pp65)

Borg, N.et al. (2005). The CDR3 regions of an immunodominant T cell receptor dictate the ‘energetic landscape’ of peptide-MHC recognition. Nat. Immunol. 6: 171-180. [PubMedID:15640805]

B*08:01/FLRGRAYGL (EBV EBNA-3A)

Burrows, JM. et al. (2008) Preferential binding of unusually long peptides to MHC class I and its influence on the selection of target peptides for T cell recognition. Mol. Immunol. 45: 1818-1824. [PubMedID:17981331]

B*35:01/QPAPENAYQAY (EBV BZLF)

Davies et al (2012) Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation. Cell Transplantation. [PubMedID:22507909]

Davies, JK et al (2008). Induction of alloanergy in human donor T cells without loss of pathogen or tumour immunity. Transplantation. 86: 854-864 [PubMedID:18813111]

A*02:01/GLCTLVAML (EBV BMLF-1)
A*02:01/NLVPMVATV (CMV pp65)

de Angelis, B. et al. (2009) Generation of Epstein-Barr virus specific cytotoxic T lymphocytes resistant to the immunosuppresive drug tacrolimus (FK506). Blood. 114: 4784-4791 [PubMedID:19759356]

A*11:01/IVTFDSVIK (EBV EBNA3B)
A*11:01/AVFDRKSDAK (EBV EBNA3B)
B*08:01/QAKWRLQTL (EBV EBNA3A)
B*08:01/RAKFKQLL (EBV BZLF1)

Elliott, S. et al. (2007). A phase I trial of a CD8+ T cell peptide epitope-based vaccine for infectious mononucleosis. J. Virol. 82: 1448-57. [PubMedID:18032491]

B*08:01/FLRGRAYGL (EBV EBNA-3A)
B*08:01/RAKFKQLL (EBV BZLF-1)

Fox C. et al. (2010). A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 116:19 3695-3704. [PubMedID:20671118]

Frumento et al (2012) Cord Blood T Cells Retain Early Differentiation Phenotype Suitable for Immunotherapy After TCR Gene Transfer to Confer EBV Specificity. American J. Transplant. [PubMedID:23016879]

A*11:01/SSCSSCPLSK (EBV LMP-2 340-349)

Fuji et al (2011) Adoptive immunotherapy with virus-specific T cells. Best Practice & Research Clinical Haematology 24:413 [PubMedID: 21925094]

Fujita, Y. et al. (2008) Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapy. J Immunother. 31: 665-674. [PubMedID:18600178]

B*35:01/MPNRPNYIAF (Adenovirus 5 Hexon)
A*02:01/NLVPMVATV (CMV pp65)
A*02:01/FLYALALL (EBV LMP-2)
A*02:01/CLGGLLTMV (EBV LMP-2)

Gandhi, M.K. et al. (2007). Galectin-1 mediated suppression of EBV-specific T-cell immunity in classical Hodgkin-s lymphoma. Blood 110: 1326-9. [PubMedID: 17438085]

A*02:01/CLGGLLTMV (EBV LMP-2)

Gandhi, M.K. et al. (2007). Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. Am. J. Transplant. 7: 1293-1299. [PubMedID:17425621]

B*08:01/FLRGRAYGL (EBV EBNA-3A)

Gandhi, M.K. et al. (2006). Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T cell function in Hodgkin lymphoma patients. Blood 108: 2280-2289. [PubMedID:16757686]

A*02:01/GLCTLVAML (EBV BMLF-1)
A*02:01/CLGGLLTMV (EBV LMP-2)
B*07:02/RPPIFIRRL (EBV EBNA-3A)
B*08:01/FLRGRAYGL (EBV EBNA-3A)
B*08:01/RAKFKQLL (EBV BZLF-1)

Gras, S et al. (2010). Allelic polymorphism in the T cell receptor and its impact on immune responses. J. Exp. Med 207: 1555-67.[PubMedID:20566715]

B35:01/HPVGEADYFEY

Griffioen, M. et al (2008). Genetic engineering of virus-specific T cells with T-cell receptors recognizing minor histocompatibility antigens for clinical application. Haematologica. 93: 1535-1543 [PubMedID:18768532]

Han, S. et al. (2009). Phenotype and functional evaluation of ex vivo generated antigen-specific immune effector cells with potential for therapeutic applications. J. Hematol & Oncol. 2: 34. [PubMedID:19660111]

A*24:02/TYGPVFMCL (EBV LMP2)

Hanley et al (2011) Expansion of T cells targeting multiple antigens of cytomegalovirus, Epstein–Barr virus and adenovirus to provide broad antiviral specificity after stem cell transplantation.  Cytotherapy 13:976 [PubMedID: 21539497]

Hart, D P. et al (2008). Retroviral transfer of a dominant TCR prevents surface expression of a large proportion of the endogenous TCR repertoire in human T cells. [PubMedID:18305579]

A*02:01/CLGGLLTMV (EBV LMP-2)

Hofer, S. et al. (2005). Dendritic cells regulate T-cell de-attachment through the integrin-interacting protein CYTIP. Blood 107: 1003-1009. [PubMedID:16204317]

A*02:01/GLCTLVAML (EBV BMLF-1)

Jarvis, LB. et al. (2008) Human leukocyte antigen class I-restricted immunosuppression by human CD8+ regulatory T cells requires CTLA-4-mediated interaction with dendritic cells. Human Immunology. 69:687-695 [PubMedID:18817831]

Jochum et al. (2012) The EBV immunoevasins vIL-10 and BNLF2a Protect newly infected B cells from immune recognition and elimination. PLoS Pathogens 8: e1002704 [PubMedID:22615564]

Jones, K. et al. (2010) Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood 116:2245-2252 [PubMedID:20562330]

B*08:01/YNLRRGIAL
B*08:01/YNLRRGTAL

Karlsson, H. et al. (2007) Generation of trispecific cytotoxic T cells recognizing cytomegalovirus, adenovirus and Epstein-Barr virus. J. Immunother. 30: 544-556. [PubMedID:17589295]

A*02:01/NLVPMVATV (HCMV pp65)
B*07:02/RPHERNGFTVL (HCMV pp65)
B*07:02/TPRVTGGGAM (HCMV pp65)
A*02:01/CLGGLLTMV (EBV LMP-2)
A*02:01/GLCTLVAML (EBV BMLF-1)
B*07:02/RPPIFIRRL (EBV EBNA-3A)
B*08:01/RAKFKQLL (EBV BZLF-1)
A*24:02/TYFSLNNKF (Adenovirus 5 Hexon)
A*01:01/TLDGQNLLY (Adnovirus 5 Hexon)
B*07:02/KPYSGTAYNAL (Adenovirus Hexon)

Karlsson, H. et al. (2008). Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T cell responses. Blood 112: 532-541 [PubMedID:18445691]

A*02:01/NLVPMVATV (HCMV pp65)
B*07:02/RPHERNGFTVL (HCMV pp65)
B*07:02/TPRVTGGGAM (HCMV pp65)
A*02:01/GLCTLVAML (EBV BMLF-1)
B*07:02/RPPIFIRRL (EBV EBNA-3A)
B*08:01/RAKFKQLL (EBV BZLF-1)

Keymeulen et al (2010) Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. Blood 115:1145 [PubMedID:20007541]

Landmeier, S. et al. (2009). Activated humangd T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes. J. Immunother. 32: 310-321 [PubMedID: 19242369]

A*02:01/FLYALALLL (EBV LMP-2)
B*08:01/RAKFKQLL (EBV BZLF-1)

Lehner, M. et al. (2007). Efficient chemokine-dependent migration and primary and secondary IL-12 secretion by human dendritic cells stimulated through Toll-like receptors. J Immunother. 30: 312-322. [PubMedID: 17414322]

A*02:01/GLCTLVAML (EBV BMLF-1)

Louis, CU. et al. (2008). Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood. 113: 2442-2450. [PubMedID: 18971421]

A*11:01/AVFDRKSDAK (EBV EBNA3B)

Lutzky, VP. et al. (2009). Optimization of LMP-specific CTL expansion for potential adoptive immunotherapy in NPC patients. Immunol & Cell Biol. 87: 481-488.[PubMedID: 19468283]

A*11:01/SSCSSCPLSK (EBV LMP-2)

Miles, J.J. et al. (2006). TCRa genes direct MHC restriction in the potent human T cell response to a class I-bound viral epitope. J. Immunol. 177: 6804-6814. [PubMedID: 17082594]

B*35:01/HPVGEADYFEY (EBV EBNA-1)

Moosman et al (2010) Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells 115:2960 [PubMedID:20103780]

Moran et al (2011) Epstein-Barr Virus Gene Expression, Human Leukocyte Antigen Alleles and Chronic High Viral Loads in Pediatric Renal Transplant Patients. Transplantation 92:328 [PubMedID: 21685826]

Mustjoki, S. et al. (2009) Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 23(8):1398-1405. [PubMedID: 19295545]

Nehring, A.K. et al. (2007). Epstein-Barr virus T-cell immunity despite rituximab. Br. J. Haematol. 136: 628-632. [PubMedID: 17223914]

B*08:01/FLRGRAYGL (EBV EBNA-3A)

Neller et al (2012) Tracking the repertoire of human adult and neonatal T cells during ex vivo amplification. British Journal of Haematology [PubMedID:22924682]

Qi, Z et al (2014) Recombinant Covalently Closed Circular Hepatitis B Virus DNA Induces Prolonged Viral Persistance in Immunocompetant Mice. Journal of Virology. [Published Online] [PubMedID: 24807718]

H-2Kb/VWLSVIWM (ENV 353)

Reker Hadrup, S. et al. (2006). Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional cytomegalovirus-specific T cells in the very elderly. J. Immunol. 176: 2645-2653. [PubMedID: 16456027]

A*02:01/NLVPMVATV (HCMV pp65)
A*02:01/GLCTLVAML (EBV BMLF-1)
A*02:01/ILKEPVHGV (HIV-1 pol 476-484)

Ruiss et al (2011) A VLP-based Epstein-Barr Virus vaccine. Journal of Virology 85:13105[PubMedID: 21994444]

Samarasinghe et al (2010) Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. Blood 115:396[PubMedID:19890093]

Sandalova et al (2010) Contribution of herpesvirus specific CD8 T cells to anti-viral T cell response in humans. PloS Pathogens 6:e1001051 [PubMedID:20808900]

Schultz-Thater, E. et al. (2008). Whole blood assessment of antigen specific cellular immune response by real time quantitative PCR: a versatile monitoring and discovery tool. Journal of Translational Medicine. 6: 58 [PubMedID: 18925935]

A*02:01/NLVPMVATV (CMV (pp65)
A*02:01/GLCTLVAML (EBV BMLF1)
A*02:01/CLGGLLTMV (EBV LMP2)
A*02:01/GILGFVFTL (Influenza MP)

Smith, C. et al. (2009) Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self aggregation. Blood. 113: 6148-6152. [PubMedID: 19372256]

B*35:01/YPLHEQHGM (EBV EBNA-3A)
B*35:01/IPSINVHHY (CMV pp65)
A*02:01/NLVPMVATV (CMV pp65)
A*02:01/YLQQNWWTL (EBV LMP-1)
A*02:01/CLGGLLTMV (EBV LMP-2)

Smith, C. et al. (2009). Acquisition of polyfunctionality by Epstein-Barr virus-specific CD8+ T cells correlates with increased resistance to galectin-1 mediated suppression. J Virol. 83: 6192-6198. [PubMedID: 19357166]

A*02:01/CLGGLLTMV (EBV LMP-2)
B*08:01/FLRGRAYGL (EBV EBNA-3A)

Smith, C. et al.(2006).; Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope. J. Immunol. 177: 4897-4906. [PubMedID: 16982932]

A*02:01/CLGGLLTMV (EBV LMP-2)
B*35:01/HPVGEADYFEY (EBV EBNA-1)

Suneetha, PV. et al. (2009). Effect of peptide pools on effector functions of antigen-specific CD8+ T cells. J Immunol. Methods 342: 33-48. [PubMedID: 19135447]

A*02:01/GILGFVFTL (Influenza MP)
A*02:01/NLVPMVATV (CMV pp65)
A*02:01/GLCTLVAML (EBV BMLF-1)
A*02:01/CINGVCWTV (HCV NS3)

Tellam, J. et al. (2007). Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes. J. Exp. Med. 204: 525-532. [PubMedID: 17312009]

B*08:01/FLRGRAYGL (EBV EBNA-3A)

Tellam, J. et al. (2007). Translation efficiency of EBNA1 encoded by lymphocryptoviruses influences endogenous presentation of CD8+ T cell epitopes. Eur. J. Immunol. 37: 328-337. [PubMedID: 17236233]

B*08:01/FLRGRAYGL (EBV EBNA-3A)

Tellam, J. et al. (2008). Regulation of protein translation through mRNA structure influences MHC class I loading and T cell recognition. PNAS. 105: 9319-9324 [PubMedID: 18591662]

B*35:08/HPVGEADYFEY (EBV EBNA1)

Tellam, J. et al (2012). Messenger RNA Sequence Rather than Protein Sequence Determines the Level of Self-synthesis and Antigen Presentation of the EBV-encoded Antigen, EBNA1. PLoS Pathogens 8(12) [PubMedID:23300450]

Tey et al (2012) Autophagy mediates transporter associated with antigen processing-independent presentation of viral epitopes through MHC class I pathway. Blood [PubMedID:22723550]

Tey, S-K. et al. (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol. Blood Marrow Transplant. 13: 913-24. [PubMedID: 17640595]

B*08:01/RAKFKQLL (EBV BZLF-1)
A*02:01/NLVPMVATV (CMV pp65)

Tuuminen, T. et al. (2007). Human CD8 T cell memory generation in Puumala Hantavirus infection occurs after the acute phase and is associated with boosting of EBV-specific CD8 memory T cells. J.Immunol. 179: 1988-1995.

A*02:01/GLCTLVAML (EBV BMLF-1)

Tynan, F.E. et al. (2007). A T cell receptor flattens a bulged antigenic peptide presented by a major histocompatability complex class I molecule. Nat. Immunol 8: 268-276. [PubMedID: 17259989]

Tynan, F.E. et al. (2005). T cell receptor recognition of a ‘super-bulged’ major histocompatibility complex class I-bound peptide. Nat. Immunol. 6: 1114-1122. [PubMedID: 16186824]

Uhlin et al (2012) Rapid Salvage Treatment With Virus-Specific T Cells for Therapy-Resistant Disease. Clincal Infectious Diseases [PubMedID:22806594]

Vera, JF. et al. (2009). Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Molecular Therapy.17: 880-888.[PubMedID: 19259067]

B*08:01/RAKFKQLL (EBV BZLF-1)
B*08:01/QAKWRLQTL (EBV EBNA-3A)
A*02:01/GLCTLVAML (EBV BMLF-1)

Wang et al (2009) Lentiviral calnexin-modified dendritic cells promote expansion of high-avidity effector T cells with central memory phenotype.Immunology 128:43 [PubMedID:19689735]

(back to top)

 

Hepatitis B Virus (HBV)

Bayard et al (2010) Hepatitis B virus (HBV)-derived DRB1*0101-restricted CD4 T-cell epitopes help in the development of HBV-specific CD8+ T cells in vivo. Vaccine 28:3818 [PubMedID: 20362206]

Boettler, T. et al. (2006). Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionality and phenotypically defined memory T cells during acute resolving hepatitis B virus infection. J. Virology. 80: 3532-3540. [PubMedID:16537621

A*02:01/FLPSDFFPSV (HBV core)
A*02:01/FLLTRILTI (HBV envelope)
A*02:01/WLSLLVPFV (HBV surface antigen)
A*02:01/GLSRYVARL (HBV polymerase)

Carey, I. et al. (2010). Immune and viral profile from tolerance to Hepatitis B Surface Antigen clearance: a longitudinal study in vertically HBV infected children on combined therapy. Journal of Virology. 85:2416 [PubMedID: 21147914]

A*02:01/FLPSDFFPSV (HBV core)

Chen et al. (2012). Enhanced Peripheral γδT Cells Cytotoxicity Potential in Patients with HBV-Associated Acute-On-Chronic Liver Failure Might Contribute to the Disease Progression. Journal of Clinical Immunology [PubMedID:22415432]

Chen et al. (2011). Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B. Antiviral Research 91:23 [PubMedID: 21549152]

Chen et al. (2010). Pegylated interferon α-2b up-regulates specific CD8+ T cells in patients with chronic hepatitis B. World Journal of Gastroenterology 16:6145 [PubMedID:21182232]

Chen, W. et al. (2008). HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes. Hepatology Research. 39:355-365 [PubMedID: 19889409]

A*02:01/FLPSDFFPSV (HBV core)

Chen, W. et al. (2008) Activated plasmacytoid dendritic cells act synergistically with hepatitis B core antigen-pulsed monocyte-derived dendritic cells in the induction of hepatitis B virus-specific CD8 T-cell response. Clinical Immunol. 129-295-303 [PubMedID: 18774748]

A*02:01/FLPSDFFPSV (HBV core)

Das et al (2012) IL-10–Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection. Journal of Immunology [PubMedID:22972930]

Deng et al (2009) Hepatitis B virus as a gene delivery vector activating foreign antigenic T cell response that abrogates viral expression in mouse models.  Hepatology 50:1380[PubMedID:19821533]

Evans, A. et al. (2008). Programmed death 1 (PD-1) expression during antiviral treatment of chronic hepatitis B: Impact of HBeAg Seroconversion. Hepatology. 48: 759-769 [PubMedID: 18697210]

A*02:01/FLPSDFFPSV (HBV core)
A*02:01/FLLTRILTI (HBV sAg)
A*02:01/NLVPMVATV (CMV pp65)

Gehring, A.J. et al. (2007). The level of viral antigen presented by hepatocytes influences CD8 T cell function. J. Virol. 81: 2940-2949. [PubMedID: 17202217]

Gehring, A.J. et al. (2010). Engineering Virus-Specific T cells that Target HBV Infected Hepatocytes and Hepatocellular Carcinoma Cell lines Journal of Hepatology. 55:103 [PubMedID: 21145860]

Gu et al (2012) Effect of oxymatrine on specific cytotoxic T lymphocyte surface programmed death receptor-1 expression in patients with chronic hepatitis B. Chinese Medical Journal 125:1434[PubMedID:22613649]

Gu et al. (2009). Comparison and significance of specific and non-specific cellular immunity in patients with chronic hepatitis B caused by infection with genotypes B or C of hepatitis B virus. Sci China C Life Sci. 52:719 [PubMedID: 19727589]

Kennedy et al (2008) The expression and function of NKG2D molecule on intrahepatic CD8+ T cells in chronic viral hepatitis.  Journal of Viral Hepatitis 15:901 [PubMedID:19087227]

Komatsu, H. et al .(2010).  Cellular immunity in children with successful immunoprophylactic treatment for mother-to-child transmission of hepatitis B virus.  BMC Infectious Diseases 10: 103-113 [PubMedID:20423521]

A*24:02/EYLVSFGVW (HBV pol 756-764)
A*24:02/KYTSFPWLL (HBV core 117-125)

Lai, Q et al (2014) TCRγδ+CD4−CD8− T Cells Suppress the CD8+ T-Cell Response to Hepatitis B Virus Peptides, and Are Associated with Viral Control in Chronic Hepatitis B. PLoS One. 9(2). e88475. [PubMedID: 24551107]

Larson et al (2010) Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses. International Journal of Pharmaceutics. 414:312 [PubMedID:21601626]

Li et al (2012) Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8+ T cell in HCC patients. Immunology Letters. Epub ahead of print. [PubMedID:23261718]

Li et al (2010) Hansenula polymorpha expressed heat shock protein gp96 exerts potent T cell activation activity as an adjuvant. Journal of Biotechnology 151:343 [PubMedID:21167226]

Li et al (2011) Dynamic changes of cytotoxic T lymphocytes (CTLs), natural killer (NK) cells, and natural killer T (NKT) cells in patients with acute hepatitis B infection. Virology Journal 8:199  [PubMedID:21535873]

Liu et al (2012) IL-2–Engineered nano-APC Effectively Activates Viral Antigen-Mediated T Cell Responses from Chronic Hepatitis B Virus-Infected Patients. Journal of Immunology 188:1534[PubMedID:22210908]

Liu, H-G. et al. (2007). The high prevalence of the I27 mutant HBcAg18-27 epitope in Chinese HBV-infected patients and its cross-reactivity with the V27 prototype epitope. Clin. Immunol. 125: 337-45. [PubMedID:17900990]

A*02:01/FLPSDFFPSV (HBV core)
A*02:01/FLPSDFFPSI (HBV core)

Lopes, AR. et al. (2008). Bim-mediated deletion of antigen-specific CD8+ T cells in patients unable to control HBV infection. J. Clin. Invest. 118: 1835-1845 [PubMedID: 18398508]

A*02:01/FLPSDFFPSV (HBV core)
A*02:01/FLLTRILTI HBV env)
A*02:01/GLSRYVARL (HBV pol)

Lv et al (2010) Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment. Virology Journal7:207 [PubMedID:20807412]

Nystrom, J. et al. (2010) Improving on the Ability of Endogenous Hepatitis B Core Antigen to Prime Cytotoxic T Lymphocytes.  Journal of Infectious Diseases 201: 1867-1879 [PubMedID:20446851]

H-2Kb/MGLKFRQL (HBcAg 93-100

Pan et al (2011) The analysis of CD45 isoforms expression on HBV-specific T cells after liver transplantation. Medical Oncology epub ahead of print [PubMedID:21279700]

Peng et al (2011) Hepatitis B e-antigen Persistency is Associated with the Properties of HBV-Specific CD8 T Cells in CHB Patients. Journal of Clinical Immunology31:195 [PubMedID:21120686]

Peng, G. et al. (2007). PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol. Immunol. 45: 963-70. [PubMedID:17868872]

A*02:01/FLPSDFFPSV (HBV core)
A*11:01/YVNVNMGLK (HBV core)

Phillips, S. et al. (2010). CD8+ T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J. Immunol. 184: 287-295 [PubMedID:19949099]

A*02:01/FLPSDFFPSV (HBV core)

Poggi et al (2005) Regulation of γδ T cell survival by soluble HLA-I: Involvement of CD8 and activating killer Ig-like receptors. European Journal of Immunology 35:2670 [PubMedID:16114098]

Sandalova et al (2012) Increased levels of Arginase in patients with acute hepatitis B suppress antiviral T cells. Gastroenterology [PubMedID:22475535]

Schiott et al. (2011). Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses. Int. J. Pharma. 414:312 [PubMedID:21601626]

Schirmbeck, R. et al. (2008). The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Molecular Therapy. 16: 1609-1616 [PubMedID:18612271]

H-2Ld/IPQSLDWWTSL (HBV SAg)

Schurich, A. et al. (2011). Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology. 53:1494 [PubMedID: 21360567]

Wieland, A. et al. (2009). Silencing an immunodominant epitope of hepatitis B surface antigen reveals and alternative repertoire of CD8 T cell epitopes of this viral antigen. Vaccine. 23: 114-119 [PubMedID:19818719]

H-2Ld/IPQSLDWWTSL (HBV SAg)

Wortmann, A. et al. (2007). Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 16: 154-62. [PubMedID:17848961]

H-2Ld/IPQSLDSWWTSL (HBV surface antigen )

Wu et al (2012) Blockade of Tim-3 signaling restores the virus-specific CD8+T-cell response in patients with chronic hepatitis B. European Journal of Immunology 42:1180 [PubMedID:22539292]

Wu et al (2010) Soluble CD40 ligand-activated human peripheral B cells as surrogated antigen presenting cells: A preliminary approach for anti-HBV immunotherapy. Virology Journal 7:370[PubMedID:21176236]

Wu et al (2004) Alteration in Cellular Immunity after Chronic Hepatitis B Deteriorated into Severe Hepatitis and Its Significance.  Hepatitis Monthly. 11:810 .[PubMedID:22224079]

Xibing et al (2011) Frequencies of epitope-specific cytotoxic T lymphocytes in active chronic viral hepatitis B infection by using MHC class I peptide tetramers.  Immunology Letters. 92:235 .[PubMedID: 22224079]

Xibing, G. et al (2011). Alteration in Cellular Immunity after Chronic Hepatitis B Deteriorated into Severe Hepatitis and Its Significance. Hepatitis Monthly 11(10) [PubMedID: 22224079]

Yang et al (2012) A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy Journal of Viral Hepatitis epub.

Yang L., et al (2011) Presence of valine at position 27 of the hepatitis B virus core gene is associated with severe liver inflammation in Chinese patients.  Journal of Medical Virology. 83(2):218-24.[PubMedID:21181915]

A*02:01/FLPSDFFPSV (HBV core)

Ye et al (2008) Programmed death-1 expression is associated with the disease status in hepatitis B virus infection.  World J Gastroenterol. 14:4551 [PubMedID:18680238]

Zhang et al (2010) Regulatory T cells in chronic hepatitis B patients affect the immunopathogenesis of hepatocellular carcinoma by suppressing the anti-tumour immune responses. Journal of Viral Hepatitis (special issue) 17:34.

Zhang, Z. (2009) Dynamic decrease in PD-1 expression correlates with HBV-specific memory CD8 T-cell developmet in acute self-limited hepatitis B patients. J. Hepatol. 50: 1163-1173 [PubMedID: 19395117]

A*02:01/FLLTRILTI (HBV env)
A*02:01/WLSLLVPFV (HBV SAg)
A*02:01/FLLSLGIHL (HBV pol)
A*02:01/NLVPMVATV (CMV pp65)
A*02:01/GILGFVFTL (Influenza MP)

Zhang et al (2008) Dynamic Programmed Death 1 Expression by Virus-Specific CD8 T Cells Correlates With the Outcome of Acute Hepatitis B. Gastroenterology 134:1938[PubMedID:18455515]

(back to top)

 

Hepatitis C Virus (HCV)

Barnes et al (2012) Novel Adenovirus-Based Vaccines Induce Broad and Sustained T Cell Responses to HCV in Man. Science Translational Medicine 4:115ra1 [PubMedID:22218690]

Bengsch et al (2010) Coexpression of PD-1, 2B4, CD160 and KLRG1 on Exhausted HCV-Specific CD8+ T Cells Is Linked to Antigen Recognition and T Cell Differentiation. PloS Pathogens 6:e1000947 [PubMedID:20548953]

Caetano, J. et al. (2008). Differences in Hepatitis C Virus (HCV)-specific CD8 T-cell phenotype during pegylated alpha interferon and ribavirin treatment are related to response to antiviral therapy in patients chronically infected with HCV . J.Virol. 82: 7567-7577. [PubMedID:18480446]

A*02:01/CINGVCWTV (HCV N53)
A*02:01/DLMGYIPAV (HCV core)

Chen, A. et al. (2011) . Heterologous T Cells Can Help Restore Function in Dysfunctional Hepatitis C Virus Nonstructural 3/4A-Specific T Cells during Therapeutic Vaccination.  Journal of Immunology. 186: In Press [PubMedID: 21430225]

Choi, YS et al. (2014) Relationshiip between Poor Immunogenicity of HLA-A2-Restricted Peptide Eiptoopes and Paucity of Naive CD8+ T-Cell Precursors in HLA-A2-Transgenitc Mice. Immune Network. 14:4, pp. 219-225. [PubMedID:25177254]

Desjardins et al (2009) Recombinant retrovirus-like particle forming DNA vaccines in prime-boost immunization and their use for hepatitis C virus vaccine development.  Journal of Gene Medicine 11:313 [PubMedID:19248137]

Franceschini et al (2012) Polyfunctional Type-1, -2, and -17 CD8+ T Cell Responses to Apoptotic Self-Antigens Correlate with the Chronic Evolution of Hepatitis C Virus Infection PLoS Pathogens 8:e1002759 [PubMedID:22737070]

Fournillier, A. et al (2013) A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus. Journal of Infectious Disease 208(6)[PubMedID: 23776192]

Fytili, P. et al. (2008) Cross-genotype-reactivity of the immunodominant HCV CD8 T-cell epitope NS3-1073. Vaccine. 26: 3818-3826 [PubMedID: 18582999]

A*02:01/CINGVCWTV (HCV NS3)

Golden-Mason, L. et al.(2008). Cutting Edge: Programmed Death-1 expression is increased on immunocytes in chronic hepatitis C virus and predicts failure of response to antiviral therapy: Race-dependent differences. J. Immunol. 180: 3637-3641. [PubmedID: 18322167]

B*35:01/HPNIEEVAL (HCV NS3)

Golden-Mason, L. et al. (2007). Upregulation of PD-1 expression on circulating and intrahepatic HCV-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 81: 9249-58. [PubMedID:17567698]

Golden-Mason, L. et al. (2009) Negative immune regulatory Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells. J. Virol. 83: 9122-9130 [PubMedID:19587053]

A*02:01/KLVALGINAV (HCV NS3)
A*02:01/CINGVCWTV (HCV NS3)

Grabowski et al. (2011). Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Liver International. 31:1395 [PubMedID:21762356]

Hoare et al. (2013). GammaH2AX+CD8+ T-lymphocytes cannot respond to Interferon-alpha, Il-2 or IL-6 in chronic hepatitis C virus infection. J. Hepatol. epub [PubMedID:23257612]

A*02:01/KLVALGINAV (HCV NS3 1406-1415)

Holmstrom et al. (2013). A synthetic codon-optimized Hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice. J. Immunol. 190 [PubMedID:23284053]

H2Kb/VILDSFDPL (HCV NS5A 2251-2259)
H2Kb/MGLKFRQL (HBV core)

Huang et al. (2004). Identification of novel HLA-A*0201-restricted CD8+ T-cell epitopes on hepatitis delta virus. Journal of General Virology. 85:3089 [PubMedID:15448372]

Jeong, H-Y. et al. (2007). Blocking of monocyte-associated B7-H1 (CD274) enhances HCV-specific T cell immunity in chronic hepatitis C infection. J. Leukoc. Biol. 83: 755-64. [PubMedID:18086898]

A*02:01/CINGVCWTV (HCV N53)

Kasprowicz, V. et al. (2007). High PD-1 expression on HCV-specific CD8+ and CD4+ T cells during acute Hepatitis C irrespective of clinical outcome. J. Virol. 82: 3154-60. [PubMedID:18160439]

A*02:01/CINGVCWTV(HCV N53)
A*02:01/KLVALGINAV

Kasprowicz, V. et al 2008). Defining the directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals infected with hepatitis C virus. J. Clin.Invest. 118: 1143-1153 [PubMedID:18246203]

A*02:01/GILGFVFTL (Influenza MP)
A*02:01/CVNGSCFTV (Influenza NA)

Kasprowicz, V. et al (2010). HCV sequence variation induces an HCV-specific T cell phenotype analogous to spontaneous resolution. J. Virol. 84: 1656-1663 [PubMedID: 19906915]

A*01:01/ATDALMGTY (HCV NS3)
A*02:01/CINGVCWTV (HCV NS3)
A*02:01/GLQDCTMLV (HCV NS5B)
B*07:02/GPRLGVRAT (HCV core)

Langhans, B. et al. (2006). Presentation of the HCV-derived lipopeptide LP20-44 by dendritic cells enhances function of in vitro-generated CD4+ T cells via up-regulation of TLR2.Vaccine 24: 3066-3075. [PubMedID: 16504351]

A*02:01/YLLPRRGPRL (HCV core)

Larrubia et al (2011) Bim-mediated apoptosis and PD-1/PD-L1 pathway impair reactivity of PD1+/CD127− HCV-specific CD8+ cells targeting the virus in chronic hepatitis C virus. Cellular Immunology 269:104 [PubMedID: 21481848]

Larrubia et al (2012) Persistent hepatitis C virus (HCV) infection impairs HCV-specific cytotoxic T cell reactivity through Mcl-1/Bim imbalance due to CD127 down-regulation. Journal of Viral Hepatitis

McMahan et al (2010) Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro Journal of Clinical Investigation 120:4546 [PubMedID:21084749]

Mengshol et al (2010) A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection PLoS One 4: e9504 [PubMedID:20209097]

Morishima et al (2010) Silymarin Inhibits In Vitro T-Cell Proliferation and Cytokine Production in Hepatitis C Virus Infection. Gastroenterology 138:671 [PubMedID:19782083]

Pasatto et al (2012) TCR-Redirected Human T Cells Inhibit Hepatitis C Virus Replication: Hepatotoxic Potential Is Linked to Antigen Specificity and Functional Avidity. J. Immunol. 189(9):4510-19 [PubMedID:23024278]

Pasatto et al (2012) Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3.  Journal of General Virology epub [PubMedID:22071510]

Pasetto et al (2010) Generation of T cell receptors targeting a genetically stable and immunodominant cytotoxic T lymphocyte epitope within the hepatitis C virus non-structural 3 protein. Journal of General Virology 93:247 [PubMedID:22071510]

Rutebemberwa, A. et al. (2008). High-programmed death-1 levels on hepatitis C virus-specific T cells during acute infection are associated with viral persistence and require preservation of cognate antigen during chronic infection. J. Immunol. 181: 8215-8225 [PubMedID: 19050238]

A*01:01/ATDALMTGY (HCV NS3)
A*02:01/RLWHYPCTV (HCV E23)

Smyk-Pearson, S. et al. (2008). Spontaneous recovery in acute human HCV infection: functional T cell thresholds and relative importance of CD4 help. J. Virol. 82: 1827-37. [PubMedID:18045940]

A*02:01/CINGVCWTV

Tan, WG. et al. (2017) Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens. PLoS One. 12(7). [PubMedID:28732046]

(back to top)

 

Human Herpes Virus (HHV/HSV)

Martin et al (2012) Specific CD8+ T cells recognize human herpesvirus 6B. European Journal of Immunology. [PubMedID:22886850]

Soberman et al (2012) CD200R1 Supports HSV-1 Viral Replication and Licenses Pro-Inflammatory Signaling Functions of TLR2. PLoS One 7:e47740. [PubMedID:23082204]

H2Kd/SSIEFARL (HSV-1 gp B 498-505)

(back to top)

 

Human Immunodeficiency Virus (HIV)

Almeida, J. et al. (2007). Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204: 2473-85. [PubMedID:17893201]

B*27:05/KRWIILGLNK (HIV-1 gag p24)
A*03:01/QVPLRPMTYK (HIV-1 nef)
A*03:01/RLRPGGKKK (HIV-1 gag p17)
B*07:02/GPGMKARVL (HIV-1 gag)

Andersen, MH. et al. (2005). Spontaneous immunity against Bcl-XL in cancer patients.J. Immunol. 175: 2709-2714. [PubMedID:16081848

A*02:01/ILKEPVHGV (HIV-1 pol)

Bailey, JR. et al. (2008). Transmission of human immunodeficiency virus type I from a patient who developed AIDS to an elite suppressor. J Virol. 82: 7395-7410 [PubMedID: 18495769]

B*27:05/KRWIILGLNK (HIV-1 gag p24)

Breckpot, K. et al. (2010). HIV-1 Lentiviral Vector Immunogenicity is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7. Journal of Virology. 84: 5627 [PubMedID:20237085]

H-2Kb/SIINFEKL

Bridgeman, A. et al. (2009). Ovine atadenovirus, a novel and highly immunogenic vector in prime-boost studies of a candidate HIV-1 vaccine. Vaccine. 28: 474-483 [PubMedID:19853074]

H-2Kd/AMQMLKETI (HIV-1)

Brockman, MA. et al. (2009). IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood. 114: 346-356. [PubMedID:19365081]

A*02:01/SLYNTVATL (HIV-1 gag)
B*27:05/KRWIILGLNK (HIV-1 gag)

Caivano et al (2010) HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells. Virology 407:296 [PubMedID:20850858]

Chapuis, A. et al. (2011). HIV-specific CD8+ T cells from HIV+ individuals receiving HAART can be expanded ex vivo to augment systemic and mucosal immunity in vivo. Blood. In Press. [PubMedID:21422474]

Chevalier et al (2011) HIV-1-Specific Interleukin-21 CD4 T Cell Responses Contribute to Durable Viral Control through the Modulation of HIV-Specific CD8 T Cell Function. Journal of Virology 85:733[PubMedID:21047960]

Chew, GM et al (2016) TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection. PLoS Pathogens. 12(1)[PubMedID:26741490]

Cooper, D. et al. (2008). Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and G gene truncation reduces neurovirulence and enhances immunogenicity in mice. J. Virol. 82: 207-19. [PubMedID:17942549]

H-2Kd/AMQMLKETI (HIV gag)

Cottingham, M.G. et al. (2006). Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies. Clin. Vaccine Immunol. 13: 747-757. [PubMedID: 16829611]

H-2Dd/RGPGRAFVTI (HIV-1 gp120

Decrion, A.Z. et al. (2007). A subset of functional effector-memory CD8+ T lymphocytes in human immunodeficiency virus-infected patients. Immunology 121: 405-15. [PubMedID:17376193]

A*02:01/ILKEPVHCV (HIV Pol)
A*02:01/SLYNTVATL (HIV gag)
A*02:01/GLCTLVAML (EBV BMLF-1)
A*02:01/NLVPMVATV (CMV pp65)

Denning, W., et al (2011) Limited Transplantation of Antigen-expressing Hematopoietic Stem Cells Induces Long-Lasting Cytotoxic T cell Responses PLoS One, 6:e16897

H-2Kb/SIINFEKL (Ovalbumin)

Earl, PL. et al. (2009). Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines. Vaccine. 27: 5885-5895. [PubMedID: 19654066]

H-2Kd/AMQMLKETI (HIV-1)

Eriksson et al (2012) Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity. Blood 119:745[PubMedID:22134167]

Favre D., et al (2011) HIV disease progression correlates with the generation of dysfunctional naive CD8low T cells. Blood. 117(7):2189-99. [PubMedID: 21200021]

A*02:01/NLVPMVATV (CMV pp65)
A*02:01/ELAGIGILTV (MelanA/MART-1)

Goldoni et al (2011) Mucosal and systemic anti-GAG immunity induced by neonatal immunization with HIV LAMP/gag DNA vaccine in mice.Immunobiology 216:505 [PubMedID:20870310]

Harari, A. et al. (2008). An HIV-1 clade C DNA prime, NYVAC boost regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 205: 63-77 [PubMedID: 18195071]

A*01:01/YSENSSEYY (HIV-1 env)

Jones, RB. et al. (2008). Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frqeuencies in progressive HIV-1 infection. J. Exp. Med. 205: 2763-2779 [PubMedID: 19001139]

Kloverpris et al (2009) Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 23:1329[PubMedID:19528789]

Korsholm, K, et al (2013). Broadening of the T-Cell Repertoire to HIV-1 Gag p24 by Vaccination of HLA-A2/DR Transgenic Mice with Overlapping Peptides in the CAF05 Adjuvant. PLoS One 8(5)[PubMedID:23691069]

Lecuroux et al (2009) Antiretroviral therapy initiation during primary HIV infection enhances both CD127 expression and the proliferative capacity of HIV-specific CD8+ T cells.  AIDS 23:1649[PubMedID:19617814]

Lecuroux, C. et al. (2009). Identification of a particular HIV-specific CD8+ T cells subset with a CD27+ CD45RO/RA+ phenotype and memory characterisation after initiation of HAART during acute primary HIV infection. 113: 3209-3217 [PubMedID: 19098272]

Li Pira et al (2012) Selective binding of CD4 and CD8 T-cells to antigen presenting cells for enrichment of CMV and HIV specific T-lymphocytes J Immunol Methods. 376:125[PubMedID:22251662]

Liard et al (2011). Targeting of HIV-p24 particle-based vaccine into differential skin layers induces distinct arms of the immune responses. Vaccine 29:6379 [PubMedID: 21554912]

Lichterfeld, M. et al. (2008). Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1in progressors. Blood. 112: 3679-3687 [PubMedID: 18728248]

Lichterfield, M. et al. (2007). A viral CTL escape mutation leading to immunoglobulin-like transcript 4-mediated functional inhibition of myelomonocytic cells. J. Exp. Med. 204: 2813-24. [PubMedID:18025130]

B*27:05/KRWIILGLNK (HIV-1 gag)
B*27:05/KRWIIMGLNK HIV-1 gag)

Nakagawa et al (2012) Induction of rapid apoptosis for class I MHC molecule-restricted CD8+ HIV-1 gp160-specific murine activated CTLs by free antigenic peptide in vivo. International Immunology[PubMedID:22945875]

Pajot et al (2007) The Th1 immune response against HIV-1 Gag p24-derived peptides in mice expressing HLA-A02.01 and HLA-DR1.  European Journal of Immunology 37:2635[PubMedID:17668896]

Papagno et al (2011) Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine AIDS 25:27 [PubMedID:21076273]

Ratto-Kim et al (2012) Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens. PLoS One. 7(9):e45840 [PubMedID:23049876]

AMNQMLKDTI
H2Kd/AMQMLKETI (HIV-1 gag p24 199-207>

Rawson, P.M. et al. (2007). Cross-presentation of caspase-cleaved apoptotic self antigens in HIV infection. Nat. Med. 13: 1431-1439. [PubMedID:18026114]

A*02:01/LLQDSVDFSL (Vimentin)
A*02:01/QLFNHTMFI (Non-muscle myosin)
A*02:01/VLMIKALEL (Non-muscle myosin)
A*02:01/FLGMESCGI (Actin)

Rigato et al (2010) Immunization of neonatal mice with LAMP/p55 HIV gag DNA elicits robust immune responses that last to adulthood Virology 406:37 [PubMedID:20667577]

Robey et al. (2011) Ex-Vivo Recognition of Late-Lytic CD8 Epitopes Specific for Kaposi’s Sarcoma-Associated Herpesvirus (KSHV) by HIV/KSHV-Coinfected Individuals.  Viral Immunology 24:211 [PubMedID: 21668362]

Roshorm et al (2009) Novel HIV-1 clade B candidate vaccines designed for HLA-B*5101+ patients protected mice against chimaeric ecotropic HIV-1 challenge. European Journal of Immunology 39:1831 [PubMedID:19585509]

Saez-Cirion, A. et al. (2009). Heterogeneity in HIV Suppression by CD8 T cells from HIV controllers: Association with gag-specific CD8 T cell responses. J. Immunol. 182: 7828-7837. [PubMedID: 19494307]

A*02:01/SLYNTVATL (HIV-1 gag)
A*02:01/ILKEPVHGV (HIV-1 pol)
A*03:01/RLRPGGKKK (HIV-1 gag)
A*03:01/QVPLRPMTYK (HIV-1 nef)
B*27:05/KRWIILGLNK (HIV-1 gag)

Salisch, NC. et al. (2010). Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. J Immunol. 184: 476-487. [PubMedID: 19949078]

A*02:01/SLYNTVATL (HIV-1 gag)
A*03:01/RLRPGGKKK (HIV-1 gag)
A*03:01/QVPLRPMTYK (HIV-1 nef)
B*07:02/IPRRIRQGL (HIV-1 env)
B*08:01/EIYKRWII (HIV-1 gag)
B*08:01/FLKEKGGL (HIV-1 nef)
B*27:05/KRWIILGLNK (HIV-1 gag)

Sauce et al (2007) PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 21:2005 [PubMedID:17885290]

Schnuriger et al (2009) Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 23:2079[PubMedID:19710595]

Shen et al (2011)A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV) Virology Journal 8:265 [PubMedID:21624130]

Shephard, E. et al. (2008). A multigene HIV type 1 subtype C modified vaccinia ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res. Hum. Retroviruses. 24: 207-217. [PubMedID:18240963]

H-2Dk/VYYDPSKDLIA (HIV-RT)
H-2Dd/RGPGRAFVTI (HIV-env)

Simonetta et al (2012) Early and Long-Lasting Alteration of Effector CD45RA-Foxp3high Regulatory T-Cell Homeostasis During HIV Infection. Journal of Infectious Diseases 205:1510[PubMedID:22457280]

Streek et al (2011) Epithelial adhesion molecules can inhibit HIV-1–specific CD8+ T-cell functions Blood 117:5112 [PubMedID:21403126]

Streeck, H. et al. (2008). Antigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cells. PLoS Medicine. 5: e100 [PubMedID: 18462013]

Streeck, H. et al. (2008). Immune-driven recombination and loss of control after HIV superinfection. J Exp. Med. 205: 1789-1796 [PubMedID: 18625749]

B*27:05/KRWIIMGLNK (HIV-1 gag p24)

Subramanya et al (2010) Enhanced Induction of HIV-specific Cytotoxic T Lymphocytes by Dendritic Cell-targeted Delivery of SOCS-1 siRNA Molecular Therapy 18:2028 [PubMedID:20648001]

Ting, T et al (2017) Differential Potency and Breadth of the Same Epitope-Specific CTLs to Inhibit HIV-1 Replication based on TCR Usage. Journal of AIDS and Clinical Research. doi: 10.4172/2155-6113.1000735

Turnbull et al (2009) Kinetics of Expansion of Epitope-Specific T Cell Responses during Primary HIV-1 Infection. Journal of Immunology 182:7131 [PubMedID:19454710]

Vinner et al. (2011). Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries. APMIS 119:487 [PubMedID: 21749448]

Vali, B. et al. (2008). HIV-specific T-cells accumulate in the liver in HCV/HIV co-infection. PLoS one. 3: e3454. [PubMedID: 18941622]

Vali, B. et al. (2010). Characterization of cross-reactive CD8+ T-cell recognition of HLA-A2-restricted HIV-Gag: SLYNTVATL and HCV-NS5b: ALYDVVSKL epitopes in individuals infected with Human Immunodeficiency and Hepatitis C Viruses. Journal of Virology [PubMedID: 20980521]

A*02:01/SLYNTVATL (HIV-1 gag)

Vollbrecht et al (2010) Impact of changes in antigen level on CD38/PD-1 co-expression on HIV-specific CD8 T cells in chronic, untreated HIV-1 infection. Journal of Medical Virology 82:358[PubMedID:20087935]

Yang et al (2010) Mutational Escape in HIV-1 CTL Epitopes Leads to Increased Binding to Inhibitory Myelomonocytic MHC Class I Receptors PLoS One 5:e15084 [PubMedID:21170342]

Yu, X. et al. (2007). Random T-cell receptor recruitment in human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cells from genetically identical twins infected with the same HIV-1 strain. J. Virol. 81: 12666-9. [PubMedID: 17804503]

B*40:01/IEELRQHLL (HIV-1 pol)
B*40:01/IETVPVKL (HIV-1 pol)
B*40:01/KEKGGLEGL (HIV-1 nef)
A*02:01/YTAFTIPSV (HIV-1 pol)
A*02:01/SLYNTVATL (HIV-1 gag)

Zhang et al. (2011). B and T lymphocyte attenuator down-regulation by HIV-1 depends on type I interferon and contributes to T-cell hyperactivation. Journal of Infectious Diseases 203:1668 [PubMedID:21592997]

Zhang et al. (2006). Characteristics of HIV-1-specific CD8 T-cell responses and their role in loss of viremia in children chronically infected with HIV-1 undergoing highly active antiretroviral therapy. Chinese Journal of Medicine. 119:1949 [PubMedID:17199938]

Zhang, J-Y. et al. (2007). PD-1 upregulation is correlated with HIV-specific memory CD8+ T cell exhaustion in typical progressors, but not in long-term non-progressors. Blood 109:4671-4678. [PubMedID:17272504]

A*02:01/SLYNTVATL (HIV-1 gag p17)

Zhang et al (2009) Progressive CD127 down-regulation correlates with increased apoptosis of CD8 T cells during chronic HIV-1 infection. European Journal of Immunology 39:1425[PubMedID:19350559]

(back to top)

 

Human Papillomavirus (HPV)

Narayan et al (2009) Epithelial expression of human papillomavirus type 16 E7 protein results in peripheral CD8 T-cell suppression mediated by CD4+CD25+ T cells. European Journal of Immunology 39:481 [PubMedID:19180468]

(back to top)

 

Human T-lymphotropic Virus (HTLV)

Hayashi, D. et al.(2008). Reduced Foxp3 expression with increased cytomegalovirus-specific CTL in HTLV-1-associated myelopathy. J Neuroimmunol. 200: 115-124 [PubMedID: 18639344]

A*02:01/LLFGYPVYV (HTLV Tax)
A*02:01/CLGGLLTMV (CMV LMP2)
A*02:01/NLVPMVATV (CMV pp65)
A*02:01/SLYNTVATL (HIV gag17)

Kawabata et al (2012) Human T-lymphotropic virus type I (HTLV-I)-specific CD8+ cells accumulate in the lungs of patients infected with HTLV-I with pulmonary involvement. Journal of Medical Virology 84:1120 [PubMedID:22585731]

Manuel, SL. et al. (2009). Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatry disease. J. Leukoc. Biol. 86: 86: 1205-1216 [PubMedID: 19656902]

A*02:01/LLFGYPVYV (HTLV-1 Tax)

Matsuura, E. et al. (2008). Inclusion body myositis associated with human T-lymphotropic virus-type I infection: Eleven patients from an endemic area in Japan. J Neuropathol Exp Neurol. 67: 41-49. [PubMedID: 19656902]

A*02:01/LLFGYPVYV (HTLV Tax)
A*02:01/GILGFVFTL (Influenza MP)

Ndhlovu et al (2011) HTLV-1 Tax Specific CD8+ T Cells Express Low Levels of Tim-3 in HTLV-1 Infection: Implications for Progression to Neurological Complications. PLoS Neglected Tropical Diseases. 5: e1030 [PubMedID: 21541358]

Oliveira, ALA. et al (2009). High frequencies of functionally competent circulating Tax-specific CD8+T cells in human T lymphotropic virus type 2 (HTLV-2) infection. J Immunol. 183: 2957-2965 [PubMedID: 19657093]

A*02:01/LLYGYPVYV (HTLV-2 Tax-2)
A*02:01/NLVPMVATV (CMV pp65)
A*03:01/ILRGSVAHK (Influenza NP)
B*35:01/IPSINVHHY (CMV pp65)

(back to top)

 

Lymphocytic Choriomeningitis Virus (LCMV)

Boettler et al (2012) TGF-β Blockade Does Not Improve Control of an Established Persistent Viral Infection Viral Immunology 25:232 [PubMedID:22620718]

Coppieters et al (2009) No Significant CTL Cross-Priming by Dendritic Cell-Derived Exosomes during Murine Lymphocytic Choriomeningitis Virus Infection. Journal of Immuology 182:2213[PubMedID:19201875]

Fousteri, G. et al. (2009). CD103 is dispensable for anti-viral immunity and autoimmunity in a mouse model of virally-induced autoimmune diabetes. J. Autoimmunity. 32: 70-77 [PubMedID:19162441]

H-2Db/KAVYNFATC (LCMV gp33)
H-2Db/FQPQNGQFI (LCMV NP)

Fousteri et al (2011) Increased Memory Conversion of Naïve CD8 T Cells Activated during Late Phases of Acute Virus Infection Due to Decreased Cumulative Antigen Exposure. PLoS One 6: e14502 [PubMedID: 21253594]

Joeckel et al (2012) IL-1R signaling is essential for induction of pro-apoptotic CD8 T cells, viral clearance and pathology during LCMV infection in mice. Journal of Virology [PubMedID:22674984]

Pardo, J. et al. (2008). Granzyme B-induced cell death exerted by ex vivo CTL: discriminating requirements for cell death and some of its signs. Cell Death Differ. 15: 567-579. [PubMedID:18064039]

H-2Db/KAVYNFATC (LMCV gp33)

Schnell et al. (2012). Lymphocytic Choriomeningitis Virus Infection in FVB Mouse Produces Hemorrhagic Disease. PLoS Path. 8:e1003073. [PubMedID:23300439]

H-2Db/KAVYNFATC (LMCV gp33)
H-2Db/FQPQNGQFI (LCMV NP 396-404)
H-2Db/SGVENPGGYCL (LCMV GP 276-286)

(back to top)

 

Respiratory Syncytial Virus (RSV)

Beyer, M. et al.(2005). The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo. Respir Res. 6: 70-80. [PubMedID:16011799]

H-2Kd/SYIGSINNI (RSV M2)

Cyr, SL. et al. (2007). Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology. Vaccine. 25: 5378-5389. [PubMedID: 17561317]

H-2Kd/KYKNAVTEL (RSV A strain F protein)

DiNapoli, JM. et al. (2008). Impairment of the CD8+ T cell response in lungs following infection with human respiratory syncytial virus is specific to the anatomical site rather than the virus, antigen, or route of infection. Virology Journal. 5: 105 [PubMedID: 18816384]

H-2Kd/TYQRTRALV (Influenza NP)
H-2Kd/SYIGSINNI (RSV M2)

Eichinger, KM. et al (2017) Localization of the T-cell response to RSV infection is altered in infant mice. Pediatric Pulmonology. [Epub ahead of print] [PubMedID:29115050]

H-2Kd/KYKNAVTEL (RSV A strain F protein)

Harker et al (2010) Interleukin 18 Coexpression during Respiratory Syncytial Virus Infection Results in Enhanced Disease Mediated by Natural Killer Cells. Journal of Virology 84: 4073[PubMedID:20130064]

Harker, J. et al. (2010). Delivery of Cytokines by Recombinant Virus in Early Life Alters the Immune Response to Adult Lung Infection. Journal of Virology. 84:5294 [PubMedID: 20200251]

H-2Kd/SYIGSINNI (RSV M2)

Kochenderfer, J.N. et al. (2006). Synergism between CpG-Containing Oligodeoxynucleotides and IL-2 Causes Dramatic Enhancement of Vaccine-Elicited CD8+ T Cell Responses. J. Immunol. 177: 8860-8873. [PubMedID:17142789]

H-2Kd/SYIGSINNI (RSV M2)

Lindell et al (2011) A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease.  PLoS One 6:e21823 [PubMedID:21789184]

Loebbermann et al (2012) Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection.  Mucosal Immunology epub [PubMedID:22236998]

Pribul, P. et al. (2008). Alveolar macrophages are a major determinant of early responses to viral lung infection but do not influence subsequent disease development. J. Virol. 82: 4441-4448. [PubMedID:18287232]

H-2Kd/SYIGSINNI (RSV M2)

Smit, J.J. et al. (2008). The balance between plasmacytoid DC versus conventional DC determines pulmonary immunity to virus infections. PLoS ONE 3(3): e1720. [PubMedID:18320041

H-2Kd/SYIGSINNI (RSV M2)

Tregoning et al (2008) The Role of T Cells in the Enhancement of Respiratory Syncytial Virus Infection Severity during Adult Reinfection of Neonatally Sensitized Mice. Journal of Virology 82:4115[PubMedID:18272579]

Tregoning et al (2011) The chemokine MIP1alpha/CCL3 determines pathology in primary RSV infection by regulating the balance of T cell populations in the murine lung. PLoS One 5:e9381[PubMedID:20195359]

(back to top)

 

Vaccinia Virus

Baur, K. et al. (2010). Immediate-Early Expression of a Recombinant Antigen by Modified Vaccinia Virus Ankara Breaks the Immunodominance of Strong Vector-Specific B8R Antigen in Acute and Memory CD8 T-Cell Responses. Journal of Virology. 84(17):8743-52. [PubMedID: 20538860]

Berhanu et al (2010) Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice. Vaccine 29:289[PubMedID:21036130]

Chard, L et al (2014) A Vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Clinical Cancer Research. [Published online 21 November 2014][PubMedID: 25416195]

H-2Kb/TSYKFESV (vaccinia virus B8R/Ovalbumin)

Frenz et al (2011) Concomitant type I IFN receptor-triggering of T cells and of DC is required to promote maximal modified vaccinia virus Ankara-induced T-cell expansion. European Journal of Immunology 40:2769 [PubMedID:20821729]

Freyschmidt, E-J. et al. (2007). Skin inflammation in RelB(-/-) mice leads to defective immunity and impaired clearance of vaccinia virus. J. Allergy Clin. Immunol. 119:671-679. [PubMedID: 17336617]

Freyschmidt, E-J. et al. (2010). Skin Inflammation Arising from Cutaneous Regulatory T Cell Deficiency Leads to Impaired Viral Immune Responses. J. Immunol. 185:1295-302. [PubMedID:20548030]

H-2Kb/TSYKFESV (vaccinia virus B8R)

Jiang et al (2012) Skin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity Nature 483:227 [PubMedID:22388819]

Kremer et al (2012) Critical Role of Perforin-dependent CD8+ T Cell Immunity for Rapid Protective Vaccination in a Murine Model for Human Smallpox PloS Pathogens 8:e1002557[PubMedID:22396645]

Laouar, A. et al. (2008) Concurrent generation of effector and central memory CD8 T cells during vaccinia virus infection. PLoS one. 3: e4089 [PubMedID: 19116651]

H-2Kb/TSYKFESV (vaccinia virus B8R)

Lorente et al (2011) Multiple Viral Ligands Naturally Presented by Different Class I Molecules in Transporter Antigen Processing-Deficient Vaccinia Virus-Infected Cells. Journal of Virology 86:527[PubMedID:22031944]

Luckashenak, N. et al. (2008). Constitutive crosspresentation of tissue antigens by dendritic cells control CD8+ T cell tolerance in vivo. Immunity. 28: 521-532. [PubMedID: 18387832]

H-2Kb/TSYKFESV (vaccinia virus B8R)

Oyoshi, MK. et al. (2009). Vaccinia virus inoculation in sites of allergic skin inflammation elicits a vigorous cutaneous IL-17 response. PNAS 106: 14954-14959. [PubMedID: 19706451]

H-2Kb/TSYKFESV (vaccibia virus B8R)

Rosenthal, R. et al. (2009). Differential responsiveness to IL-2, IL-7 and Il-15 common receptor gchain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patients. J Immunother. 32: 252-261. [PubMedID: 19242375]

A*02:01/SLSAYIIRV (Vaccinia Virus H3L)
A*02:01/KVDDTFYYV (Vaccinia Virus C7L)

Samuelsson, C. et al. (2008). Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection. J. Clin. Invest. 118: 1776-1784 [PubMedID: 18398511]

H-2Kb/TSYKFESV

Tian et al (2012) Disruption of TNF-α/TNFR1 Function in Resident Skin Cells Impairs Host Immune Response against Cutaneous Vaccinia Virus Infection Journal of Investigative Dermatology epub[PubMedID:22318381]

(back to top)